Kenneth Carl Anderson is Director of C4 Therapeutics, Inc.. Currently has a direct ownership of 140,574 shares of CCCC, which is worth approximately $345,812. The most recent transaction as insider was on Jan 22, 2021, when has been sold 1,548 shares (Common Stock) at a price of $3.07 per share, resulting in proceeds of $4,752. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 141K
3.96% 3M change
20.46% 12M change
Total Value Held $345,812

Kenneth Carl Anderson Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 22 2021
BUY
Exercise of conversion of derivative security
$4,752 $3.07 p/Share
1,548 Added 1.85%
81,924 Common Stock
Oct 06 2020
BUY
Conversion of derivative security
-
18,040 Added 18.33%
80,376 Common Stock
KCA

Kenneth Carl Anderson

Director
Watertown, MA

Track Institutional and Insider Activities on CCCC

Follow C4 Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CCCC shares.

Notify only if

Insider Trading

Get notified when an C4 Therapeutics, Inc. insider buys or sells CCCC shares.

Notify only if

News

Receive news related to C4 Therapeutics, Inc.

Track Activities on CCCC